StemCell extends RosetteSep deal with Applied Imaging
This article was originally published in Clinica
Applied Imaging has renewed its exclusive supply agreement with StemCell Technologies, allowing the San Jose, California company to continue utilising StemCell's RosetteSep reagent technology in conjunction with its Ariol multiparameter cellular analysis system to isolate and analyse circulating tumour cells in cancer patients' blood samples.
You may also be interested in...
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.
The Stark Law ban on self-referrals wouldn’t apply to some physician owners of advanced imaging facilities under a CMS final rule.
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.